BOSTON, May 27, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced enhancements
to its Randomization and Trial Supply Management (RTSM) service,
ClinPhone® RTSM. PAREXEL designed the enhanced
service to simplify patient randomization and clinical supply
management and to offer greater speed and flexibility in tailoring
the service to meet the needs of clinical trials while reducing
delivery timelines. For the improvements, PAREXEL integrated the
interactive response technology acquired from ClinIntel in
October 2014 with PAREXEL's
experience in delivering RTSM services to thousands of studies to
create an enhanced fourth-generation technology platform.
"RTSM services are critical to clinical trials, helping sponsors
achieve treatment group balance, eliminate selection bias, increase
the predictability of treatment allocations, and manage trial
supplies, including minimizing drug wastage by enabling automated
site restocking." said Xavier Flinois, President, PAREXEL
Informatics. "Biopharmaceutical companies are increasingly
seeking to make drug development more efficient without
compromising patient safety or data quality. With the
fourth-generation ClinPhone RTSM service, our clients will benefit
from a streamlined system delivery process, the flexibility to make
rapid study design changes, and simpler patient and supply
management."
Enhancements to the ClinPhone RTSM service that will benefit our
customers include:
- Speed and efficiency: typically ready for use in four to eight
weeks, cutting weeks off of the standard system delivery time
- Configuration and customization: quickly tailored to meet the
demands of different phases of clinical development, local
regulators, regional requirements, and client or protocol specific
needs
- Adaptability: rapid turnaround and minimal timeline disruption
for study changes before or during the trial
The ClinPhone RTSM service has been used in more than 3,300
studies involving more than 290,000 sites and 2.4 million
patients. A recent global survey conducted by Industry
Standard Research, 2014 IRT Market Dynamics and Service Provider
Benchmarking Report, ranked ClinPhone RTSM as the leading
interactive response technology, citing it as the most
preferred and widely used solution.
ClinPhone RTSM is a key component of the Perceptive
MyTrials® platform, an integrated suite of applications
for managing clinical trials. ClinPhone RTSM is also
available through the Perceptive® Partner Program, as a
standalone RTSM solution, and as part of end-to-end
PAREXEL® Clinical Trial Supplies and Logistics solutions
to help ensure the right medication kits are received by the right
patients at the right time.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc. provides
advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered near
Boston, Massachusetts, PAREXEL
operates in 80 locations in 51 countries around the world, and had
approximately 17,440 employees in the third quarter. For more
information about PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials,
and ClinPhone are trademarks or registered trademarks of PAREXEL
International Corporation or its affiliates. All other
trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1
781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-enhances-clinphone-rtsm-service-to-simplify-and-expedite-randomization-and-trial-supply-management-for-clinical-studies-300088866.html
SOURCE PAREXEL International Corporation